Teprotumumab (Tepezza ® ), an insulin-like growth factor-1 receptor (IGF-1R) antagonist, is the first FDA-approved targeted therapy for thyroid eye disease (TED). While effective for reducing proptosis and inflammation, increasing post-marketing evidence has linked teprotumumab to auditory adverse events....
Audiologists should implement proactive baseline and monitoring audiologic assessments for patients prescribed teprotumumab, as ototoxicity risk is well-documented; this review provides updated clinical guidance on assessment and management strategies.
With teprotumumab's growing use for thyroid eye disease, audiologists are increasingly likely to encounter patients with drug-related hearing loss, making up-to-date assessment and management protocols essential.
- 01Teprotumumab (Tepezza), an IGF-1R antagonist for thyroid eye disease, is associated with ototoxicity.
- 02Ototoxic effects include sensorineural hearing loss, tinnitus, and autophony (hearing one's own voice loudly).
- 03Review updates recommended audiologic assessment protocols for monitoring teprotumumab patients.
- 04Management strategies discussed include hearing aids, monitoring intervals, and drug discontinuation considerations.
- 05Audiologists and prescribing physicians should coordinate care proactively for at-risk patients.
Teprotumumab is associated with ototoxicity including sensorineural hearing loss.
studysupportedAudiologic monitoring protocols can identify and help manage teprotumumab-associated hearing damage.
opinionpartially supported- PMID
- 42345631
- DOI
- 10.3390/audiolres16030092.
- Journal
- Audiology Research
- Publication type
- review
- Evidence level
- 5
- Population
- Patients receiving teprotumumab (Tepezza) for thyroid eye disease
- Intervention
- Teprotumumab (IGF-1R antagonist) treatment
Primary outcomes
Audiologic assessment protocols; Management strategies for teprotumumab-associated ototoxicity